TY - JOUR T1 - Thymic epithelial tumors: 10 years' experience of a Portuguese oncologic institute JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2015.PA4322 VL - 46 IS - suppl 59 SP - PA4322 AU - Madalena Reis AU - Teresa Almodôvar AU - José Duro da Costa Y1 - 2015/09/01 UR - http://erj.ersjournals.com/content/46/suppl_59/PA4322.abstract N2 - Introduction: Thymic cancer is rare. TET (thymic epithelial tumors) covers thymoma and thymic carcinoma, the first immunologically active, more differentiated and with less local aggressiveness.Objectives: Describe demographic variables, clinical presentation, staging, performed treatment and survival of patients diagnosed with TET followed in oncological institute.Methods: Retrospective analysis of medical records of patients diagnosed with TET, followed in our institute from 01-01-2004 to 30-07-2014.Results: Our sample is composed by 30 patients with a mean age of 52 years old (22 to 79 years) with equal distribution by gender. We verify a prevalence of cardiovascular comorbilities (23%) and cancer history (23%). About 43% of patients had respiratory symptoms. Eight patients were asymptomatic at diagnosis and nine patients had normal chest X-ray. The diagnosis was mostly determined by surgical biopsy, meeting 30% of patients in stage AB of the World Health Organization (WHO) and 30% in stage I of Masoaka - Koga classification. Twenty-five patients underwent surgery, of which 37% were also undergoing treatment with chemotherapy and / or radiotherapy. Five patients had immunological manifestations including Myasthenia gravis and erythroid series aplasia. Six patients had recurrence of thymoma. Survival rate at 5 and 10 years was 93% and 90% respectively.Conclusion: Our study reflects a population with a high percentage of comorbilities in particular history of cancer. There is a predominance of respiratory symptoms and immunological manifestations. The most common stages were I and AB Masoaka - Koga and WHO classification respectively. Featuring a survival rate over 90% at 5 and 10 years. ER -